Opportunities for mupirocin calcium cream in the emergency department

Journal of Emergency Medicine

Volumn 17, Issue 1, 1999, Pages 213-220

  Williford, Phillip M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Infectious; Mupirocin; Mupirocin calcium cream; Secondarily infected traumatic lesions; Skin diseases; Staphylococcus aureus; Wound infection

Indexed keywords

PSEUDOMONIC ACID;

ANTIMICROBIAL ACTIVITY; DRUG USE; FIRST AID; HUMAN; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION; WOUND CARE; WOUND HEALING; WOUND INFECTION;

EID: 0032935585     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-4679(98)00148-6     Document Type: Article

References (74)

1. Parish LC, Witkowski JA. Cutaneous bacterial infections. How to manage primary, secondary, and tertiary lesions. Postgrad Med 1992;91:119-122, 125-126, 129-130.
2. Kirsner RS, Eaglstein WH. The wound healing process. Dermatol Clin 1993;11:629-40.
3. Koopman CF. Cutaneous wound healing. An overview. Otolaryngol Clin N Am 1995;28:835-45.
4. Tonnesen MG, Anderson DC, Springer TA, et al. Adherence of neutrophils to cultured human microvascular endothelial cells. Stimulation by chemotactic peptides and lipid mediators and dependence upon the Mac-1, LFA-1, p150,95 glycoprotein family. J Clin Invest 1989;83:637-46.
5. Pollack SV. Wound healing: A review. I. The biology of wound healing. J Dermatol Surg Oncol 1979;5:389-93.
6. Kanzler MH, Gorsulowsky DC, Swanson NA. Basic mechanisms in the healing cutaneous wound. J Dermatol Surg Oncol 1986;12: 1156-64.
7. Rodgers KG. The rational use of antimicrobial agents in simple wounds and emerging medicine. Emerg Med Clin N Am 1992;10: 753-64.
8. Smack DP, Harrington AC, Dunn C, et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. JAMA 1996; 276:972-77.
9. Bergamini TM, Lamont PM, Cheadle WG, et al. Combined topical and systemic antibiotic prophylaxis in experimental wound infection. Am J Surg 1984;147:753-6.
10. Dire DJH, Coppola M, Dwer DA, et al. A prospective evaluation of topical antibiotics for uncomplicated soft-tissue lacerations (abstract). Ann Emerg Med 1991;21:45.
11. Waterman NG, Polland NT. Local antibiotic treatment of wounds. In: Maibach H, ed. Epidermal wound healing. Chicago: Yearbook Medical; 1972:267.
12. Watcher MA, Wheeland RG. The role of topical agents in the healing of full-thickness wounds. J Dermatol Surg Oncol 1989;15: 1188-95.
13. Mertz PM, Dunlap BW, Eaglstein WH. The effects of Bactroban ointment on epidermal wound healing in partial thickness wounds. In: Dobson R, Leyden JJ, Noble WC, Price JD, eds. Bactroban, Princeton: Excerpta Medica; 1985:211-5.
14. Tatnall FM, Leigh IM, Gibson JR. Comparative toxicity of antimicrobial agents on transformed human karatinocytes. J Invest Dermatol 1987;89:316.
15. Lineaweaver W, Howard R, Soucy D, et al. Topical antimicrobial toxicity. Arch Surg 1985;120:267-70.
16. Balin AK, Leong I, Carter DM. Effect of mupirocin on the growth and lifespan of human fibroblasts. J Invest Dermatol 1987;88:736-40.
17. Boyce ST, Warden GD, Holder IA. Cytotoxicity testing of topical antimicrobial agents on human keratinocytes and fibroblasts for cultured skin grafts. J Burn Care Rehabil 1995;16:97-103.
18. Leyden JJ. Review of mupirocin ointment in the treatment of impetigo. Clin Pediatr (Phila) 1992;31:549-53.
19. Booth JH, Benrimoj SI. Mupirocin in the treatment of impetigo. Int J Dermatol 1992;31:1-9.
20. Ward A, Campoli-Richards DM. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986;32:425-44.
21. SmithKline Beecham Pharmaceuticals. Bactroban cream (mupirocin calcium cream) package insert. Philadelphia, PA; 1997.
22. SmithKline Beecham Pharmaceuticals. Bactroban (mupirocin ointment 2%) package insert. Philadelphia, PA; 1992.
23. Eedy DJ. Mupirocin allergy in the setting of venous ulceration. Contact Dermatitis 1995;32:240-1.
24. Kaczmarski EB. Mupirocin in polyethylene glycol base is not suitable for application to burns. J Antimicrob Chemother 1988; 22:771.
25. Rode H, de Wet PM, Cywes S, et al. Mupirocin in a polyethylene glycol carrier base. J Antimicrob Chemother 1989a;24:78-9.
26. Sutherland R, Boon RJ, Griffin KE, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 1985;27:495-8.
27. Utrup LJ, Finlay JE, Rittenhouse SF, et al. Comparison of mupirocin susceptibility of nasal and nonnasal Staphylococcus aureus isolates. Diagn Microbiol Infect Dis 1994;20:171-4.
28. Slocombe B, Perry C. The antimicrobial activity of mupirocin - an update on resistance. J Hosp Infect 1991;19(Suppl B):19-25.
29. Bradley SF, Ramsey MA, Morton TM, et al. Mupirocin resistance: Clinical and molecular epidemiology. Infect Control Hosp Epidemiol 1995;16:354-8.
30. Kraus S, Eron L, Bottenfield G, et al: Comparison of a new formulation of mupirocin cream (MC) with oral cephalexin (C) in the treatment of secondarily infected traumatic lesions (SITL). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Session 98, 28 September-1 October, 1997, Toronto, Ontario, Canada.
31. Henkel TJ, Bottenfield G, Drehobl M, et al. Comparison of mupirocin calcium cream (MC) with oral cephalexin (C) in the treatment of secondarily infected traumatic lesions (SITLs). Poster presentation. Presented at the 97th General Meeting of the American Society for Microbiology 4-8, May, 1997, Miami Beach, FL, USA.
32. Bass JW, Chan DS, Creamer KM, et al. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Ped Infect Dis J 1997;16:708-9.
33. Rist T, Sulica V, Parish L, et al. Comparison of mupirocin cream (MC) with oral cephalexin (C) in the treatment of secondarily infected eczema (SIE). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Session 132, 15-18 September 1996, New Orleans, Louisiana, USA.
34. Gratton D. Topical mupirocin versus oral erythromycin in the treatment of primary and secondary skin infections. Int J Dermatol 1987;26:472-3
35. Welsh O, Saenz C. Topical mupirocin compared with oral ampicillin in the treatment of primary and secondary skin infections. Curr Ther Res 1987;41:114-20.
36. Dux PH, Fields L, Pollock D. 2% topical mupirocin versus systemic erythromycin and cloxacillin in primary and secondary skin infections. Curr Ther Res 1986;40:933-40.
37. Villiger JW, Robertson WD, Kanji K, et al. A comparison of the new topical antibiotic mupirocin ('Bactroban') with oral antibiotics in the treatment of skin infections in general practice. Curr Med Res Opin 1986;10:339-45.
38. Breneman DL. Use of mupirocin ointment in the treatment of secondarily infected dermatoses. J Am Acad Dermatol 1990;22: 886-92.
39. Rogers M, Dorman DC, Gapes M, et al. A three-year study of impetigo in Sydney. Med J Aust 1987;147:63-5.
40. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996:334:240-5.
41. Barton LL, Friedman AD, Sharkey AM, et al. Impetigo contagiosa: Comparative efficacy of oral erythromycin and topical mupirocin. Pediatr Dermatol 1989;6:134-8.
42. McLinn S. Topical mupirocin vs. systemic erythromycin treatment for pyoderma. Pediatr Infect Dis J 1988;7:785-90.
43. Goldfarb J, Crenshaw D, O'Hora J, et al. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrob Agents Chemother 1988;32:1780-3.
44. Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: Implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1992;36:287-90.
45. Ward A, Campoli-Richards DM. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986;32:425-44.
46. Carney JM, Bickers DR, Vehicle-controlled study of Bactroban ointment in secondary skin infections. In: Dobson R, Leyden JJ, Noble WC, Price JD, eds. Bactroban. Princeton: Excerpta Medica: 1985:242-5.
47. D'Alessandri RM, Gross J, Powers R. In: Dobson R, Leyden JJ, Noble WC, Price JD, eds. Bactroban. Princeton: Excerpta Medica; 1985:158-61.
48. DeBoer DC. A comparative study of Bactroban ointment and its vehicle in treating secondary infections of the skin. In: Dobson R, Leyden JJ, Noble WC, Price JD, eds. Bactroban. Princeton: Excerpta Medica; 1985:224-7.
49. Eaglstein WH. The efficacy and safety of Bactroban ointment and its vehicle in the treatment of secondarily infected skin lesions in children. In: Dobson R, Leyden JJ, Noble WC, Price JD, eds. Bactroban. Princeton: Excerpta Medica; 1985:120-3.
50. Golitz LE, Beehler BJ. A comparative study of Bactroban ointment and its vehicle in secondary infections of the skin. In: Dobson R, Leyden JJ, Noble WC, Price JD, eds. Bactroban. Princeton: Excerpta Medica; 1985:249-52.
51. Leyden JJ. Double blind study on the clinical and quantitative bacteriological effects of Bactroban ointment in secondarily infected dermatoses. In: Dobson R, Leyden JJ, Noble WC, Price JD, eds. Bactroban. Princeton: Excerpta Medica; 1985:253-6.
52. Orecchio RM, Mischler TW. A double-blind multiclinic comparative trial of mupirocin topical and its vehicle in the treatment of bacterial skin infections. Curr Ther Res 1986;39:82-6.
53. Pekoe GM, Dobson RL. Vehicle-controlled study of Bactroban ointment in secondary infections. In: Dobson R, Leyden JJ, Noble WC, Price JD, eds. Bactroban. Princeton: Excerpta Medica; 1985: 246-8.
54. Rosenberg EW, Churchwell MA. Treatment of infected dermatoses with Bactroban. In: Dobson R, Leyden JJ, Noble WC, Price JD, eds. Bactroban. Princeton: Excerpta Medica; 1985:257-9.
55. Whiting DA, Jacobson C, Menter MA. A comparative study of Bactroban ointment and its vehicle in patients 12 years and older with secondary infections of the skin. In: Dobson R, Leyden JJ, Noble WC, Price JD, eds. Bactroban. Princeton: Excerpta Medica; 1985:260-2.
56. Zone JJ, Weidner M. The treatment of secondary skin infections with Bactroban ointment: A vehicle-controlled study. In: Dobson R, Leyden JJ, Noble WC, Price JD, eds. Bactroban. Princeton: Excerpta Medica; 1985:763-5.
57. Lever R, Hadley K, Downey D, et al. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988;119:189-98.
58. Carter DM, Lin AN. Wound healing and epidermolysis bullosa. Arch Dermatol 1988;124:732-3.
59. Carter DM, Lin AN, Varghese MC, et al. Treatment of junctional epidermolysis bullosa with epidermal autografts. J Am Acad Dermatol 1987;17:246-50.
60. Vizcaino-Alcaide MJ, Herruzo-Cabrera R, Rey-Calero J. Efficacy of a broad-spectrum antibiotic (mupirocin) in an in vitro model of infected skin. Burns 1993;19:392-5.
61. Rode H, de Wet PM, Millar AJ, et al. Bactericidal efficacy of mupirocin in multi-antibiotic resistant Staphylococcus aureus burn wound infection. J Antimicrob Chemother 1988;21:589-95.
62. Rode H, Hanslo D, de Wet PM, et al. Efficacy of mupirocin in methicillin-resistant Staphylococcus aureus burn wound infection. Antimicrob Agents Chemother 1989b;33:1358-61.
63. Mulligan ME, Murray-Leisure KA, Ribner BS, et al. Methicillin-resistant Staphylococcus aureus: A consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993;94:313-28.
64. Wenzel RP, Nettleman MD, Jones RN, et al. Methicillin-resistant Staphylococcus aureus: Implications for the 1990s and effective control measures. Am J Med 1991;91(Suppl 3B):221S-7S.
65. SmithKline Beecham Pharmaceuticals. Bactroban nasal (mupirocin calcium) package insert. Philadelphia, PA; 1996.
66. Casewell MW, Hill RL. Minimal dose requirements for nasal mupirocin and its role in the control of epidemic MRSA. J Hosp Infect 1991;19(Suppl B):35-40.
67. Doebbeling BN, Reagan DR, Pfaller MA, et al. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994;154:1505-8.
68. Boelaert JR, De Baere YA, Geernaert MA, et al. The use of nasal mupirocin ointment to prevent Staphylococcus aureus bacteraemias in haemodialysis patients: an analysis of cost-effectiveness J Hosp Infect 1991;19(Suppl B):41-6.
69. Slaughter S, Dworkin RJ, Gilbert DN, et al. Staphylococcus aureus septic arthritis in patients on hemodialysis treatment. West J Med 1995;163:128-32.
70. Smith JM. Serum sickness-like reactions with antibiotics. N Z Med J 1995;108:258.
71. Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother 1994;33:387-401.
72. Roujeau, JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
73. Jacobs NF, Jr. Antibiotic-induced diarrhea and pseudomembranous colitis. Postgrad Med 1994;95:111-114, 117-120.
74. Polk H, Finn M. in Simmon RC, Howard RJ, eds. Chemoprophylaxis of wound infections. Surgical Infectious Diseases. New York: Appleton-Century-Crafts; 1982:471.